Asparaginase
Elspar · Enzyme
Rare AKI; pancreatitis-mediated.
Halaven · Erib
Microtubule inhibitor · approved 2010 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A microtubule inhibitor with reduced clearance in renal impairment, not direct kidney toxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Eribulin is not a recognized direct nephrotoxin. Pharmacokinetic study shows reduced clearance and ~1.5-fold higher exposure with moderate-to-severe renal impairment, supporting dose adjustment; any AKI is generally prerenal and not well quantified.Source: Tan et al., Cancer Chemother Pharmacol 2015
Prerenal AKI follows intercurrent volume loss, with no defined onset window.
Distilled from: “Exposure-related toxicity accrues across cycles; prerenal AKI follows volume loss.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Also documented as kidney-sparing
Eribulin — No characteristic renal lesion. Reduced clearance in renal impairment — adjust dose; neuropathy.
The sparedSynthetic halichondrin-B analog that inhibits microtubule growth at the plus end (a non-taxane microtubule dynamics inhibitor distinct from the taxane binding site), sequestering tubulin and arresting cells in mitosis. Used in metastatic breast cancer and liposarcoma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the Microtubule inhibitor class.
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Hematologic
Cytopenias, thrombosis, TMA
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
4 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Nov 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
A lower starting dose is recommended for patients with moderate (CLcr 30-49 mL/min) or severe (CLcr 15-29 mL/min) renal impairment. ( 8.7 )
Kidney rows of the label's dosage tables
From the ERIBULIN MESYLATE label (Nov 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 3,739 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
663 of 3,739 reports
Reported with hospitalization
1,963 of 3,739 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 696 of the 3,739 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Eribulin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Elspar · Enzyme
Rare AKI; pancreatitis-mediated.
Welireg · HIF-2α inhibitor
Anemia/hypoxia; emerging renal profile in VHL/RCC.
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
Camptosar · Topoisomerase I inhibitor
Diarrhea-driven prerenal AKI.
Elahere · Antibody-drug conjugate (FRα/DM4)
Ocular toxicity dominates; renal involvement indirect/case-level (GI volume loss).
Tasigna · BCR-ABL TKI
eGFR decline over time.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.